STOCK TITAN

Qiagen NV - QGEN STOCK NEWS

Welcome to our dedicated news page for Qiagen NV (Ticker: QGEN), a resource for investors and traders seeking the latest updates and insights on Qiagen NV.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Qiagen NV's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Qiagen NV's position in the market.

Rhea-AI Summary
QIAGEN and Myriad Genetics have announced a new master collaboration agreement to develop companion diagnostic tests in the field of cancer. The partnership aims to deliver innovative services and products to pharmaceutical companies, enabling the development and commercialization of proprietary cancer tests for the U.S. clinical market, and providing distributable companion diagnostic test kits for the global market.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.22%
Tags
partnership
-
Rhea-AI Summary
QIAGEN N.V. plans to release Q3 2023 results
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.6%
Tags
earnings
-
Rhea-AI Summary
QIAGEN launches QuantiFERON-EBV RUO assay to support research into Epstein-Barr virus (EBV) infections and related malignancies, expanding their portfolio of cell-mediated immune response tests. The assay offers valuable insights into EBV's role in diseases like post-transplant lymphoproliferative disorder (PTLD) and multiple sclerosis (MS). It has the potential to personalize immune suppressive treatment, stratify risk, and evaluate future vaccines. QuantiFERON-EBV RUO uses specific antigens to stimulate lymphocytes in whole blood, differentiating it from traditional tests. The assay complements QIAGEN's existing QuantiFERON tests for tuberculosis, COVID-19, cytomegalovirus, and nonpathogen-specific immune responses in transplant patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.7%
Tags
none
Rhea-AI Summary
QIAGEN expands its clinical decision support software, QCI Interpret, with AI-enhanced coverage of rare disease genes and improved ranking of pathogenic variants. New features save time in variant prioritization and interpretation, and provide access to complete and trusted evidence for diagnostic labs. QCI Interpret also advances somatic NGS testing for oncology with new capabilities. QCI Interpret is widely used and respected, with over 3.5 million NGS patient test cases analyzed worldwide.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.04%
Tags
AI
-
Rhea-AI Summary
QIAGEN releases Sustainability Report 2022, highlighting progress on ESG goals
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.56%
Tags
none
-
Rhea-AI Summary
QIAGEN expands eco-friendlier product line with QIAwave RNeasy Plus Mini Kit and QIAwave DNA/RNA Mini Kit, reducing plastic usage by up to 62% and cardboard by up to 58%. Kits offer same high-quality performance. QIAGEN aims to hit net-zero greenhouse gas emissions by 2050.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.23%
Tags
none
Rhea-AI Summary
QIAGEN (QGEN) reported Q2 2023 net sales of $497 million at constant exchange rates (CER), exceeding the outlook of at least $490 million CER. The company experienced a 4% decline in overall sales compared to Q2 2022, mainly due to a drop in COVID-19 sales. Adjusted diluted EPS was $0.52 CER, higher than the expected $0.50 CER. The full-year 2023 outlook for net sales was revised to at least $1.97 billion CER, with an expected 8% CER sales growth in non-COVID product groups and adjusted diluted EPS of at least $2.07 CER.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.31%
Tags
earnings covid-19
-
Rhea-AI Summary
QIAGEN's therascreen PDGFRA RGQ PCR kit has been approved by the FDA as the first companion diagnostic to detect the PDGFRA D842V mutation in patients with gastrointestinal stromal tumors. This mutation is associated with primary resistance to other drugs. The approval strengthens QIAGEN's portfolio in precision medicine, which now includes 12 FDA-approved companion diagnostics.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.37%
Tags
fda approval
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.12%
Tags
none
Rhea-AI Summary
QIAGEN N.V. plans to release Q2 2023 results on August 8, followed by a conference call on August 9. Three options are available to join the call.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.34%
Tags
earnings
Qiagen NV

NYSE:QGEN

QGEN Rankings

QGEN Stock Data

9.52B
219.40M
0.42%
75.16%
1.49%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
Netherlands
Venlo

About QGEN

qiagen is the leading global provider of sample to insight solutions to transform biological materials into valuable molecular insights. qiagen sample technologies isolate and process dna, rna and proteins from blood, tissue and other materials. assay technologies make these biomolecules visible and ready for analysis. bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. automation solutions tie these together in seamless and cost-effective molecular testing workflows. qiagen provides these workflows to more than 500,000 customers around the world in molecular diagnostics (human healthcare), applied testing (forensics, veterinary testing and food safety), pharma (pharmaceutical and biotechnology companies) and academia (life sciences research). as of june 30, 2015, qiagen employed approximately 4,400 people in over 35 locations worldwide. further information can be found at http://www.qiagen.com.